Literature DB >> 17465456

Relationship between hepatitis B virus DNA levels and liver histology in patients with chronic hepatitis B.

Jie Shao1, Lai Wei, Hao Wang, Yan Sun, Lan-Fang Zhang, Jing Li, Jian-Qiang Dong.   

Abstract

AIM: To study the relationship between hepatitis B virus (HBV) DNA levels and liver histology in patients with chronic hepatitis B (CHB) and to determine the prevalence and characteristics of hepatitis B e antigen (HBeAg) negative patients.
METHODS: A total of 213 patients with CHB were studied, and serum HBV DNA levels were measured by the COBAS Amplicor HBV Monitor test. All patients were divided into two groups according to the HBeAg status. The correlation between serum HBV DNA levels and liver damage (liver histology and biochemistry) was explored.
RESULTS: Of the 213 patients with serum HBV DNA levels higher than 10(5) copies/mL, 178 (83.6%) were HBeAg positive, 35 (16.4%) were HBeAg negative. The serum HBV DNA levels were not correlated to the age, history of CHB, histological grade and stage of liver disease in either HBeAg negative or HBeAg positive patients. There was no correlation between serum levels of HBV DNA and alanine aminotransferanse (ALT), aspartate aminotransferase (AST) in HBeAg positive patients. In HBeAg negative patients, there was no correlation between serum levels of HBV DNA and AST, while serum DNA levels correlated with ALT (r=0.351, P=0.042). The grade (G) of liver disease correlated with ALT and AST (P<0.05, r=0.205, 0.327 respectively) in HBeAg positive patients. In HBeAg negative patients, correlations were shown between ALT, AST and the G (P<0.01, and r=0.862, 0.802 respectively). HBeAg negative patients were older (35 +/- 9 years vs 30 +/- 9 years, P<0.05 ) and had a longer history of HBV infection (8 +/- 4 years vs 6 +/- 4 years, P<0.05) and a lower HBV DNA level than HBeAg positive patients (8.4 +/- 1.7 Log HBV DNA vs 9.8 +/- 1.3 Log HBV DNA, P<0.001). There were no significant differences in sex ratio, ALT and AST levels and liver histology between the two groups.
CONCLUSION: Serum HBV DNA level is not correlated to histological grade or stage of liver disease in CHB patients with HBV DNA more than 10(5) copies/mL. Compared to HBeAg positive patients, HBeAg negative patients are older and have a lower HBV DNA level and a longer HBV infection history. There is no significant difference in sex ratio, ALT and AST levels and liver histology between the two groups.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17465456      PMCID: PMC4319133          DOI: 10.3748/wjg.v13.i14.2104

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  15 in total

Review 1.  Hepatitis B e antigen-negative chronic hepatitis B.

Authors:  S J Hadziyannis; D Vassilopoulos
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

Review 2.  Management of hepatitis B: 2000--summary of a workshop.

Authors:  A S Lok; E J Heathcote; J H Hoofnagle
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

3.  Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong.

Authors:  H L Chan; N W Leung; M Hussain; M L Wong; A S Lok
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

4.  [Hepatitis B virus genotypes and alanine aminotransferase levels in HBeAg negative patients with chronic hepatitis B and liver cirrhosis].

Authors:  Jun-qian Li; Hui Zhuang; Heng Du; Xiao-hong Wang; Xue-zhang Duan
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2005-07

5.  Assessment of the COBAS Amplicor HBV Monitor Test for quantitation of serum hepatitis B virus DNA levels.

Authors:  Vincent A Lopez; Eric J Bourne; Michael W Lutz; Lynn D Condreay
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

6.  Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection.

Authors:  Henry Lik-Yuen Chan; Steven Woon-Choi Tsang; Chook-Tiew Liew; Chi-Hang Tse; May-Ling Wong; Jessica Yuet-ling Ching; Nancy Wai-Yee Leung; John Siu-Lun Tam; Joseph Jao-Yiu Sung
Journal:  Am J Gastroenterol       Date:  2002-02       Impact factor: 10.864

Review 7.  Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005.

Authors:  Hyung Joon Yim; Anna Suk-Fong Lok
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

Review 8.  Natural history and prognosis of hepatitis B.

Authors:  Giovanna Fattovich
Journal:  Semin Liver Dis       Date:  2003-02       Impact factor: 6.115

9.  Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection.

Authors:  Emanuel K Manesis; George V Papatheodoridis; Vasilios Sevastianos; Evangelos Cholongitas; Christos Papaioannou; Stephanos J Hadziyannis
Journal:  Am J Gastroenterol       Date:  2003-10       Impact factor: 10.864

10.  Clinical and histological characteristics of chronic hepatitis B with negative hepatitis B e-antigen.

Authors:  Jie Peng; Kangxian Luo; Youfu Zhu; Yabing Guo; Lian Zhang; Jinlin Hou
Journal:  Chin Med J (Engl)       Date:  2003-09       Impact factor: 2.628

View more
  22 in total

Review 1.  To treat or not to treat the "immunotolerant phase" of hepatitis B infection: A tunnel of controversy.

Authors:  Mohamed A Mekky
Journal:  World J Hepatol       Date:  2014-04-27

2.  Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma.

Authors:  Parham Safaie; Mugilan Poongkunran; Ping-Ping Kuang; Asad Javaid; Carl Jacobs; Rebecca Pohlmann; Imad Nasser; Daryl T Y Lau
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

3.  Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.

Authors:  Ni Li; Jing-Hang Xu; Min Yu; Sa Wang; Chong-Wen Si; Yan-Yan Yu
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

4.  Influence of age and HBeAg status on the correlation between HBV DNA and hepatic inflammation and fibrosis in chronic hepatitis B patients.

Authors:  Han Bai; Hongbo Liu; Xiaokai Chen; Chan Xu; Xiaoguang Dou
Journal:  Dig Dis Sci       Date:  2012-11-22       Impact factor: 3.199

Review 5.  DNA-guided hepatitis B treatment, viral load is essential, but not sufficient.

Authors:  Rafael Bárcena Marugán; Silvia García Garzón
Journal:  World J Gastroenterol       Date:  2009-01-28       Impact factor: 5.742

6.  Levels of hepatitis B virus replicative intermediate in serum samples of chronic hepatitis B patients.

Authors:  Bhupesh Singla; Anuradha Chakraborti; Bal Krishan Sharma; Shweta Kapil; Yogesh K Chawla; Sunil K Arora; Ashim Das; Radha K Dhiman; Ajay Duseja
Journal:  Mol Biol Rep       Date:  2014-04-06       Impact factor: 2.316

7.  Natural history of chronic hepatitis B virus infection based on laboratory testing.

Authors:  Zohreh Sharifi
Journal:  Iran J Public Health       Date:  2014-07       Impact factor: 1.429

8.  Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT.

Authors:  Baolin Liao; Zhanhui Wang; Siwei Lin; Ying Xu; Junqing Yi; Min Xu; Zuxiong Huang; Ying Zhou; Fuchun Zhang; Jinlin Hou
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

9.  Detection of Hepatitis B Virus Covalently Closed Circular DNA in the Plasma of Iranian HBeAg-Negative Patients With Chronic Hepatitis B.

Authors:  Zahra Tajik; Hossein Keyvani; Farah Bokharaei-Salim; Mohammad Reza Zolfaghari; Shahin Fakhim; Maryam Keshvari; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2015-09-29       Impact factor: 0.660

10.  Characteristics of an outpatient chronic hepatitis B virus infection cohort.

Authors:  Danyenne Rejane de Assis; Simone de Barros Tenore; João Renato Rebello Pinho; David Salomão Lewi; Paulo Roberto Abrão Ferreira
Journal:  Einstein (Sao Paulo)       Date:  2015 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.